Author:
Al-Azzawi Fahed,Mahmoud Israa,Haguinet François,Bate Andrew,Sessa Maurizio
Funder
Royal Library, Copenhagen University Library
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Reference33 articles.
1. Medicines Agency E. Guideline on good pharmacovigilance practices (GVP) Module IX_Signal management (Rev 1) Date of coming into effect of first version. EMA Web Page. 2017. p. 1–12.
2. European Medicine Agency. 2020 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission. 2020 [cited 2022 Feb 17]; EMA Web Page2. 2022. p. 1–100.
3. European Medicine Agency. Validation of signals from the review of individual cases. EMA Web Page. 2009. p. 1–10.
4. Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905–8.
5. Caster O, Aoki Y, Gattepaille LM, Grundmark B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf. 2020;43:479–87.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献